|
RAP2A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
8.785200E-04 |
| Normal-vs-Stage3 |
2.88680002125119E-09 |
| Normal-vs-Stage4 |
1.72689999999864E-06 |
| Stage1-vs-Stage2 |
1.471550E-01 |
| Stage1-vs-Stage3 |
2.507600E-01 |
| Stage1-vs-Stage4 |
2.944400E-01 |
| Stage2-vs-Stage3 |
5.779000E-01 |
| Stage2-vs-Stage4 |
7.106200E-01 |
| Stage3-vs-Stage4 |
8.771600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62447832963153E-12 |
| Normal-vs-AfricanAmerican |
3.353099999992E-06 |
| Normal-vs-Asian |
3.06609999944918E-07 |
| Caucasian-vs-AfricanAmerican |
1.869830E-01 |
| Caucasian-vs-Asian |
9.603200E-01 |
| AfricanAmerican-vs-Asian |
2.427600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.50269948998528E-10 |
| Normal-vs-Female |
<1E-12 |
| Male-vs-Female |
2.104200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
<1E-12 |
| Normal-vs-Age(41-60Yrs) |
8.32445223863942E-13 |
| Normal-vs-Age(61-80Yrs) |
1.91236000000039E-05 |
| Normal-vs-Age(81-100Yrs) |
7.280300E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.236400E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.358400E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.572600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.570450E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.581200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.276400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.507200E-01 |
| Classical-VS-Follicular |
1.58930002491786E-09 |
| Classical-VS-Other |
3.860800E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
2.12599999999119E-05 |
| Tall-VS-Other |
2.782600E-01 |
| Tall-VS-Normal |
9.27259999894403E-08 |
| Follicular-VS-Other |
2.529400E-01 |
| Follicular-VS-Normal |
3.064500E-02 |
| Other-VS-Normal |
1.734560E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.44590014908397E-10 |
| Normal-vs-N1 |
8.6327000003994E-07 |
| N0-vs-N1 |
5.544800E-01 |
|
|
